Accelerating Product Innovation and Availability

Improving how prevention is delivered

Developing a rich pipeline of options for HIV prevention is essential and must be guided by community priorities that define what products are needed and supported through R&D.

Once approved, interventions typically become widely available in wealthy countries within a few years time. But scaling up new options in lower and middle-income countries lags for years, even decades, with devastating effects on global health, individual lives, and the global effort to end the epidemic.

AVAC’s work supports:

The Latest on Accelerating Product Innovation

Press Release

AVAC Condemns Administration’s Further Actions to Dismantle and Deconstruct U.S. Government Vaccine Research and Delivery Infrastructure

AVAC condemns a series of actions taken by the U.S. presidential administration to dismantle U.S. leadership in research, development and delivery of lifesaving vaccines.

Infographic

Moving a Product to the Real World

To reach the UNAIDS target of 10 million PrEP users by 2025, initiations of oral PrEP alone will not be enough—and this graphic shows that the field is beginning to apply past lessons to accelerate introduction of injectable cabotegravir.

Event

Re-Imagining Prevention: Ensuring sustainable PrEP access in an evolving funding context

If you are attending the International AIDS Society Conference (IAS), be sure to join AVAC and the Ministry of Health, Zambia for a vital conversation on:

  • The impact of PEPFAR funding restrictions on prevention programs
  • Introduction plans for new PrEP options
  • Opportunities to mobilize for effective rollout and scale-up of PrEP
  • Co-hosted by: Mia Malan of Bhekisisa, and Mitchell Warren of AVAC